Yep
At $4.5m Market Cap and absolute peanuts SP, this is strategically very good.
Medivet is turning over revenue and is profitable and is the leader in this stem cell space for animals.
Medical Australia had involvement in Medivet in different parts of the chain and this deal finally shores things up so that they can guarantee a return at the most lucrative point - retail.
Finally, over time, the profit will cover more than just wages and admin costs.
Add to My Watchlist
What is My Watchlist?